29128 Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Recombinant HIV-1 Envelope Protein 

for Vaccine Use 

Description of Technology 

In pursuit of an effective vaccine to 

end the global HIV-1/AIDS pandemic, 

researchers at the Vaccine Research 

Center (‘‘VRC’’) continue to study the 

structure of HIV-1. Recently, these 

researchers have determined the threedimensional structure of the HIV-1 

Envelope trimeric ectodomain (‘‘Env’’), 

comprised of three gp120 and three 

gp41 subunits, in its prefusion, mature, 

closed conformation. 

The researchers hypothesize that 

immunization with the prefusion, 

closed HIV-1 Env protein will elicit a 

neutralizing immune response. The VRC 

researchers engineered a portion of the 

HIV-1 Env trimer to stabilize it in this 

closed conformation for use as an 

immunogen. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Vaccine for prevention of HIV-1 

infection. 

• Therapeutic vaccine for treatment 

of HIV-1 infection. 

Competitive Advantages 

• Currently, no licensed HIV-1 

vaccine exists. 

Development Stage 

• In vitro studies characterizing the 

immunogen and its interaction with HIV 

antibodies. 

• In vivo results including 

immunogenicity in rabbits and guinea 

pigs, neutralizing activity of resulting 

serum. 

Inventors: Peter D. Kwong (NIAID), 

Ivelin S. Georgiev (NIAID), Michael 

Gordon Joyce (NIAID), Marie L. Pancera 

(NIAID), Tongqing Zhou (NIAID), 

Priyamvada Acharya (NIAID), Jason J. 

Gorman (NIAID), Yongping Yang 

(NIAID), Aliaksandr A. Druz (NIAID), 

Guillaume Stewart-Jones (NIAID), Rita 

Chen (NIAID), Gwo-Yu Chuang (NIAID), 

Ulrich Baxa (NIAID), John R. Mascola 

(NIAID), Rebecca M. Lynch (NIAID), 

Baoshan Zhang (NIAID), Cheng Cheng 

(NIAID). 

Publications: Pancera M., et al. 

Structure and immune recognition of 

trimeric pre-fusion HIV-1 Env. Nature. 

2014 Oct 23; 514(7523):455–61. [PMID: 

25296255]. 

Intellectual Property: HHS Reference 

Number E–178–2014 includes U.S. 

Provisional Patent Application No. 62/ 

046,059 filed September 4, 2014; U.S. 

Provisional Patent Application No. 62/ 

136,480 filed March 21, 2015; PCT 

Application No. PCT/US2015/048729 

filed September 4, 2015; U.S. Patent 

Application No. 15/508,885 filed March 

3, 2017; and EPO Patent Application 

No. 15766697.5 filed March 29, 2017. 

Licensing Contact: Dr. Barry 

Buchbinder, 240–627–3674; 

barry.buchbinder@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize HIV-1 immunogens for 

treating or preventing HIV-1 infection. 

For collaboration opportunities, please 

contact Dr. Barry Buchbinder, 240–627– 

3674; barry.buchbinder@nih.gov. 

Dated: June 14, 2018. 

Suzanne M. Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2018–13416 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Cooperative 

Agreement (UG1) and Clinical Trial Planning 

Grant (R34) Applications. 

Date: July 13, 2018. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Anne E. Schaffner, Ph.D., 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, (301) 451–2020, 

aes@nei.nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Research 

Project Grant Applications (R01). 

Date: July 25, 2018. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 5635 

Fishers Lane, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Brian Hoshaw, Ph.D., 

Scientific Review Officer National Eye 

Institute National Institutes of Health, 

Division of Extramural Research 5635 Fishers 

Lane, Suite 1300, Rockville, MD 20892, 301– 

451–2020, hoshawb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: June 19, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13413 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Receptor Profiling and Predictive Toxicology 

(8937). 

Date: July 19, 2018. 

Time: 10:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 


daltland on DSKBBV9HB2PROD with NOTICES